If you’re asking whether you can file an Ozempic cancer lawsuit, the honest answer is that no organized cancer litigation against Novo Nordisk currently exists, and the law firms handling the main Ozempic multidistrict litigation are not accepting cancer clients as of mid-2026. The reasons are twofold: the thyroid cancer risk has been printed on the drug’s label since approval, and the human evidence that semaglutide actually causes cancer is still unsettled. That doesn’t mean a claim is impossible, but it does mean anyone considering one faces a harder path than plaintiffs suing over the injuries already driving the litigation.
What the Current Ozempic Litigation Actually Covers
The main lawsuit against Novo Nordisk is a multidistrict litigation, MDL No. 3094, consolidated in the U.S. District Court for the Eastern District of Pennsylvania under the title In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation.1U.S. District Court, Eastern District of Pennsylvania. MDL 3094 Overview It covers Ozempic, Wegovy, and Rybelsus along with Eli Lilly’s Trulicity and Mounjaro.
The injuries in the MDL are not cancer. They are severe gastroparesis (stomach paralysis), ileus, intestinal blockages, and vision loss from a condition called nonarteritic anterior ischemic optic neuropathy.2Drugwatch. Ozempic Lawsuit Plaintiffs allege that Novo Nordisk’s clinical trials were too short to catch complications like intestinal obstructions, which emerged on average about 1.6 years into treatment.3Motley Rice. Ozempic Litigation As of mid-2026, roughly 3,763 personal injury actions are pending in the MDL for gastrointestinal injuries, plus more than 100 federal lawsuits alleging vision loss. Attorneys handling the MDL have publicly indicated they are not currently taking on individuals being treated for cancer.
Why Cancer Claims Face an Uphill Battle
Two legal realities explain the absence of a dedicated cancer track.
The first is the label. Failure-to-warn claims, which are the backbone of most pharmaceutical product liability cases, generally require showing that the manufacturer hid or inadequately communicated a risk. Ozempic’s prescribing information carries an FDA boxed warning, the most serious safety alert the agency issues, telling doctors that semaglutide caused thyroid C-cell tumors in rodents at clinically relevant doses and that the tumors were dose-dependent.4FDA. Ozempic Prescribing Information (2022) The label also contraindicates the drug for anyone with a personal or family history of medullary thyroid cancer or with Multiple Endocrine Neoplasia syndrome type 2. Because the thyroid risk has been on the label from the start, a plaintiff arguing that Novo Nordisk failed to warn about it starts at a significant disadvantage.
The second reality is causation. To win a cancer lawsuit, a plaintiff needs expert testimony that semaglutide more likely than not caused their specific cancer. The FDA itself says the human relevance of the rodent findings “has not been determined,”4FDA. Ozempic Prescribing Information (2022) and the published research points in conflicting directions.
What the Science Currently Shows
A systematic review of ten randomized controlled trials covering 14,550 participants found thyroid cancer incidence under one percent among semaglutide users, with the authors concluding there was “no significant risk” and that the data supported “excluding the hypothesis of carcinogenesis” in clinical practice. The rodent effect also did not appear in primate studies.5National Library of Medicine. Semaglutide and Thyroid Cancer Systematic Review
Cutting the other way, a disproportionality analysis of the FDA’s voluntary adverse event reporting system (FAERS) covering 2004 through early 2024 found semaglutide had a reporting odds ratio of 7.61 for thyroid cancer compared with other drugs in the database. The authors cautioned that FAERS is built from voluntary, unverified reports and cannot establish causation; it functions as a signal, not proof.6National Library of Medicine. Disproportionality Analysis of FAERS Data on GLP-1 RAs and Thyroid Cancer
Broader cancer studies muddy the picture further. A JAMA Oncology analysis of over 86,000 U.S. adults with obesity found GLP-1 users had a 17 percent lower overall cancer incidence than nonusers, with reduced risks specifically for endometrial, ovarian, and meningioma cancers.7PubMed. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity A study of 170,030 U.S. adults presented at the 2025 ASCO Annual Meeting found GLP-1 users had a 7 percent lower risk of developing 14 obesity-related cancers, including thyroid and pancreatic cancer, with no elevated risk for any type studied.8ASCO. GLP-1 Receptor Agonists May Modestly Reduce Risk of Obesity-Related Cancers A Danish registry study of 39,460 patients found slightly higher cancer incidence among long-term GLP-1 users, but researchers attributed much of it to a survival effect and found no difference when death and cancer were measured together as a single outcome.9The Lancet. Long-Term Cancer Risk Associated With GLP-1 Receptor Agonists
One review summed up the state of the evidence as “conflicting,” and noted that medullary thyroid cancer is so rare that large cohort studies struggle to draw statistical conclusions about it specifically.10National Library of Medicine. GLP-1 Receptor Agonists and Thyroid Cancer Risk That is the environment in which a plaintiff would have to prove causation, and it is why cancer-focused Ozempic lawsuits have not taken off.
The FDA’s Warning Letter About Downplaying Risks
Cancer risk has not driven litigation, but it has driven FDA enforcement. In September 2025, the agency issued a warning letter to Novo Nordisk finding that a direct-to-consumer promotional video, “An Oprah Special: Shame, Blame, and the Weight Loss Revolution,” which aired on ABC in March 2024, was false and misleading. The FDA concluded the video minimized the boxed warning on thyroid C-cell tumors and omitted warnings for hypoglycemia, acute kidney injury, and suicidal ideation. The agency singled out claims in the video that described serious risks as “overhyped” or “not been shown in human studies” as dangerous to public health, and ordered Novo Nordisk to stop the misleading communications and issue corrective messaging.11FDA. Warning Letter to Novo Nordisk Inc. Whether this creates any opening for future claims about how risks were communicated to consumers, as distinct from what the prescription label said to doctors, remains to be seen.
If You Still Want to Pursue a Claim, Deadlines Matter
Even if you are not sure the litigation landscape supports a cancer case today, state statutes of limitations continue to run. Product liability deadlines vary widely, generally falling between one and six years. Kentucky, Louisiana, and Tennessee allow just one year from the date of discovery. Most states, including Pennsylvania, New Jersey, California, and New York, allow two to three years.12FindLaw. Time Limits for Filing Product Liability Cases
Many states apply a discovery rule that starts the clock when you discover, or reasonably should have discovered, both your injury and its potential cause. Some states also impose a statute of repose, an absolute outer deadline that runs from the date of sale or manufacture regardless of when an injury shows up. Deadlines can be tolled for minors, individuals who are mentally incapacitated, and in cases involving fraudulent concealment.12FindLaw. Time Limits for Filing Product Liability Cases
If you were diagnosed with thyroid cancer or another cancer you believe is linked to Ozempic, talk to a product liability attorney licensed in your state promptly. The current MDL may not be the right vehicle, and no attorney can guarantee your case will find a home given the causation problem, but the statute of limitations is running either way. Waiting to see how the science develops can foreclose your options entirely in states with the shortest windows.